Trial Profile
A Study of Trastuzumab Emtansine in Patients With HER2-Positive, Recurrent Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2018
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms HER2-CS-2
- 30 May 2018 Status changed from active, no longer recruiting to completed.
- 28 May 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2015 New trial record